ECONOMIC IMPACT OF A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION PROGRAMME IN A MEXICAN CORPORATE SETTING

被引：1
|
作者：
Huicochea-Bartelt, J. L. [1 ]
Mucino-Ortega, E. [1 ]
Vargas-Valencia, J. J. [2 ]
机构：
[1] Pfizer SA CV, Ciudad De Mexico, Mexico
[2] Econopharma Consulting SA CV, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1612
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN69
引用
收藏
页码：A277 / A277
页数：1
相关论文
共 50 条
  • [1] Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan
    Hoshi, Shu-ling
    Kondo, Masahide
    Okubo, Ichiro
    VACCINE, 2013, 31 (25) : 2762 - 2771
  • [2] CLINICAL AND ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN SINGAPORE AND HONG KONG
    Rinaldi, F.
    Hwang, S.
    Strutton, D.
    Earnshaw, S.
    Farkouh, R.
    VALUE IN HEALTH, 2010, 13 (03) : A191 - A192
  • [3] Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality
    Harboe, Zitta Barrella
    Dalby, Tine
    Weinberger, Daniel M.
    Benfield, Thomas
    Molbak, Kare
    Slotved, Hans Christian
    Suppli, Camilla H.
    Konradsen, Helle Bossen
    Valentiner-Branth, Palle
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (08) : 1066 - 1073
  • [4] Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
    Wilson, Michele
    Wasserman, Matt
    Jadavi, Taj
    Postma, Maarten
    Breton, Marie-Claude
    Peloquin, Francois
    Earnshaw, Stephanie
    McDade, Cheryl
    Sings, Heather
    Farkouh, Raymond
    INFECTIOUS DISEASES AND THERAPY, 2018, 7 (03) : 353 - 371
  • [5] Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
    Michele Wilson
    Matt Wasserman
    Taj Jadavi
    Maarten Postma
    Marie-Claude Breton
    Francois Peloquin
    Stephanie Earnshaw
    Cheryl McDade
    Heather Sings
    Raymond Farkouh
    Infectious Diseases and Therapy, 2018, 7 : 353 - 371
  • [6] Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
    Sundaram, Neisha
    Chen, Cynthia
    Yoong, Joanne
    Luvsan, Munkh-Erdene
    Fox, Kimberley
    Sarankhuu, Amarzaya
    La Vincente, Sophie
    Jit, Mark
    VACCINE, 2017, 35 (07) : 1055 - 1063
  • [7] COST-EFFECTIVENESS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN KAZAKHSTAN
    Bektur, C.
    Nurgozhin, T.
    VALUE IN HEALTH, 2015, 18 (03) : A106 - A106
  • [8] ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE WITHIN THE PRIVATE MARKET IN BRAZIL
    Souza, C. P. R.
    Moraes, J. C.
    Berezin, E.
    Monteiro, R.
    Presa, J.
    Almeida, G.
    VALUE IN HEALTH, 2010, 13 (03) : A190 - A190
  • [9] Evaluation of appropriateness of vaccination procedures of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in a hospital setting
    Coleman, Paige
    Sears, Matthew
    Vaichys, Sabina
    Nemecek, Branden
    Guarascio, Anthony
    PHARMACOTHERAPY, 2015, 35 (11): : E305 - E305
  • [10] COST-EFFECTIVENESS OF 13-VALENT AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION RELATIVE TO 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA
    Whillans, F.
    Kwan, H.
    Strutton, D. R.
    Earnshaw, S. R.
    Farkouh, R.
    VALUE IN HEALTH, 2009, 12 (07) : A425 - A425
12345